三博脑科医院管理集团股份有限公司 累积投票实施制度 第一章 总则 第一条 为进一步完善三博脑科医院管理集团股份有限公司（以下简称"公 司"）法人治理结构，规范公司选举董事（不包括职工董事）的行为，保证股东 充分行使权利，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司治理准则》《深圳证券交易所创业板股票上市规则》及《公司章程》的相 关规定，特制定本制度。 第二条 本制度所称累积投票制，是指公司股东会在选举两名或两名以上董 事时，股东所拥有的投票权数等于其所持有的股份数乘以该次股东会应选董事人 数之积，股东可以将其拥有的投票权数全部投向一位董事候选人，也可以将其拥 有的投票权数分散投向多位董事候选人，按得票多少依次决定董事人选。 第三条 本制度适用于选举或变更两名或两名以上的董事的议案。股东会仅 选举一名董事时，不适用累积投票制。由职工代表担任的董事由公司职工代表大 会、职工大会或者其他形式民主选举产生，不适用本制度的相关规定。 姓名、性别、年龄、国籍、教育背景、详细工作经历、全部兼职情况、与提名人 的关系，与公司或公司的控股股东及实际控制人是否存在关联关系，持有的公司 股份数量，是否受过中国证 ...

三博脑科医院管理集团股份有限公司 重大信息内部报告制度 （二）公司控股股东、实际控制人、持有公司 5%以上股份的其他股东； （三）公司各部门其他对公司重大事件可能知情的人士。 第四条 董事会秘书应将内部重大信息在第一时间向董事长汇报，涉及董事 会审核范围内的事项经董事长批准后由董事会审议，需对外披露的事项在向董事 第一章 总则 第一条 为规范三博脑科医院管理集团股份有限公司（以下简称"公司"或"本 公司"）重大信息的内部报告工作，保证公司内部重大信息依法及时归集和有效管 理，确保公司信息披露的真实、准确、完整、及时，维护投资者的合法权益，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《深圳证券交易所创业板股票上市规则》（以下 简称"《创业板上市规则》"）等法律法规和《三博脑科医院管理集团股份有限公司 章程》（以下简称"《公司章程》"）的相关规定，结合公司实际情况，制定本制度。 本制度所指"重大信息"是指对公司股票及其衍生品种交易价格可能或者已经 产生较大影响的信息。 "尚未公开"是指尚未在中国证券监督管理委员会（以下简称"中国证监会"）指 定的 ...

Core Viewpoint - Sanbo Brain Science announced a revenue of 827 million yuan for the first half of 2025, representing a year-on-year growth of 17.54%, and a net profit of 69.6957 million yuan, with a year-on-year increase of 4.60% [1] Financial Performance - The company's revenue for the first half of 2025 reached 827 million yuan, marking a 17.54% increase compared to the previous year [1] - The net profit for the same period was 69.6957 million yuan, reflecting a growth of 4.60% year-on-year [1] Dividend Policy - The company plans not to distribute cash dividends, issue bonus shares, or convert reserves into additional shares [1]

三博脑科医院管理集团股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市 公司的关联 | 上市公司核算 | 2025 年期初 | 2025 年半年度占 用累计发生金额 | 2025 年半年度占 用资金的利息（如 | 2025 年半年度偿 | 2025 年 6 月 30 日 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关系 | 的会计科目 | 占用资金余额 | （不含利息） | 有） | 还累计发生金额 | 占用资金余额 | 原因 | | | 控股股东、实际控制人 | 无 | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际控制人 | 无 | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | | 小计 | ...

根据《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管 指引第2号——创业板上市公司规范运作》及相关格式指引等有关规定，三博脑 科医院管理集团股份有限公司（以下简称"公司"或"三博脑科"）将2025年半年 度募集资金存放、管理与使用情况专项说明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 证券代码：301293 证券简称：三博脑科 公告编号：2025-033 三博脑科医院管理集团股份有限公司 2025年半年度募集资金存放、管理与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 经中国证券监督管理委员会（以下简称"中国证监会"）证监许可〔2023〕 534 号文《关于同意三博脑科医院管理集团股份有限公司首次公开发行股票注 册的批复》同意注册，并经深圳证券交易所同意，公司首次公开发行人民币普 通股（A 股）39,612,900 股，每股面值人民币 1.00 元，发行价格为 29.60 元/股。 本次发行募集资金总额 117,254.1840 万元；扣除发行费用（不含增值税）后， 募集资金净额为 106,163.91 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-034 三博脑科医院管理集团股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召开第三届董事会第十四次会议，审议通过了《关于修订<公司章程>的议案》。 一、《公司章程》修订情况 为贯彻落实最新法律法规要求，进一步完善公司治理，提升公司规范运作水 平，根据《公司法》《上市公司章程指引》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等相关规定，《公司法》中监事会的职权由董事会审计委员会行使。公司《监事 会议事规则》等与监事会相关的制度相应废止。 基于此，公司对《公司章程》部分条款进行了修订，具体情况如下： | 修订前 | 修订后 | | | --- | --- | --- | | 第一章 总则 | 第一章 | 总则 | | 第一条 为维护三博脑科医院管理集团股份有限公司 | 第一条 | 为维护三博脑科医院管理集 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-035 三博脑科医院管理集团股份有限公司 关于召开2025年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 三博脑科医院管理集团股份有限公司（以下简称"公司"）第三届董事会第 十四次会议决定于 2025 年 9 月 11 日召开公司 2025 年第一次临时股东会，现将 本次股东会有关事项通知如下： 1 1、股东会届次：2025 年第一次临时股东会 2、股东会的召集人：公司董事会。公司第三届董事会第十四次会议审议通 过了《关于召开 2025 年第一次临时股东会的议案》，决定召开本次股东会。 3、会议召开的合法、合规性：本次股东会的召开符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》的相关规定。 4、会议召开的日期、时间： （1）现场会议时间：2025 年 9 月 11 日 15:00 （2）网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易系 统进行网络投票的具体时间为：2025 年 9 月 11 日 9:15-9:25,9:30-11:30 和 13:0 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-031 监事会认为：董事会编制和审议公司《2025 年半年度报告全文》及摘要的 程序符合法律法规、深圳证券交易所有关规定的要求，报告的内容能够真实、准 确、完整地反映公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗 漏 表决结果：3 票同意，0 票反对，0 票弃权。 三博脑科医院管理集团股份有限公司 第三届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 三博脑科医院管理集团股份有限公司（以下简称"公司"）第三届监事会第 十二次会议于 2025 年 8 月 25 日在公司会议室以现场结合通讯的方式召开。会议 通知于 2025 年 8 月 15 日以电子邮件方式发出。本次会议应出席监事 3 人，实际 出席监事 3 人，会议由监事会主席蒋慧敏女士主持，董事会秘书列席了会议。本 次会议的召集、召开和表决程序符合《公司法》等法律法规和《公司章程》的有 关规定。 二、监事会会议审议情况 经与会监事认真审议，会议形成了如下决议： （一）审议通过《202 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-030 三博脑科医院管理集团股份有限公司 第三届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 三博脑科医院管理集团股份有限公司（以下简称"公司"）第三届董事会第十 四次会议于 2025 年 8 月 25 日在公司会议室以现场结合通讯的方式召开。会议通 知于 2025 年 8 月 15 日以电子邮件等方式发出。本次会议应出席董事 9 名，实际 出席的董事 9 人，会议由董事长张阳先生主持，公司监事、高级管理人员列席了 会议。本次会议的召集、召开和表决程序符合《公司法》等法律法规和《公司章 程》的有关规定。 二、董事会会议审议情况 经与会董事认真审议，会议形成了如下决议： （一）审议通过《2025 年半年度报告全文》及摘要 经审议，公司董事会认为：公司 2025 年半年度报告的编制符合相关法律法 规及《公司章程》的有关规定，报告真实、准确、完整地反映了公司 2025 年半 年度的财务状况和经营情况，不存在虚假记载、误导性陈述或重大遗漏。 表决结果： ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) This section provides essential disclaimers, lists the report's structure, and defines key terms for clarity [Important Notice](index=2&type=section&id=Important%20Notice) The board, supervisory board, and senior management guarantee the report's accuracy and completeness, with no interim dividend or bonus share plans - The company's board of directors, supervisory board, and senior management guarantee the report's truthfulness, accuracy, and completeness, assuming legal responsibility[3](index=3&type=chunk) - Company head Zhang Yang, chief accountant Qiao Minghao, and accounting department head Gao Jinling declare the financial report is true, accurate, and complete[3](index=3&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[4](index=4&type=chunk) [Table of Contents](index=3&type=section&id=Table%20of%20Contents) This section lists the eight main chapters of the semi-annual report, covering company profile, management discussion, governance, and financial statements - The report comprises eight main chapters, covering comprehensive information on company operations, finance, governance, and risks[6](index=6&type=chunk) - Reference documents include signed and sealed financial statements, the full and summary semi-annual reports, and originals of all publicly disclosed company documents and announcements[8](index=8&type=chunk)[9](index=9&type=chunk)[10](index=10&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines common terms used in the report, including company names, subsidiaries, regulatory bodies, and specific reporting periods - "Company," "the Company," "Joint Stock Company," and "Sanbo Brain Hospital" refer to Sanbo Brain Hospital Management Group Co, Ltd[12](index=12&type=chunk) - "Reporting Period" refers to January 1, 2025, to June 30, 2025[12](index=12&type=chunk) - "Prior Period" refers to January 1, 2024, to June 30, 2024[12](index=12&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=Company%20Profile%20and%20Key%20Financial%20Indicators) This section provides the company's basic information, contact details, and a summary of key financial data and performance metrics [Company Profile](index=6&type=section&id=%E4%B8%80%E3%80%81Company%20Profile) This section introduces the company's basic information, including its stock ticker "Sanbo Brain Hospital" and stock code "301293" - Stock Abbreviation: Sanbo Brain Hospital, Stock Code: **301293**[14](index=14&type=chunk) - Company Chinese Name: Sanbo Brain Hospital Management Group Co, Ltd[14](index=14&type=chunk) - Legal Representative: Zhang Yang[14](index=14&type=chunk) [Contact Persons and Information](index=6&type=section&id=%E4%BA%8C%E3%80%81Contact%20Persons%20and%20Information) This section provides contact details for the company's board secretary and securities affairs representative for investor communication - Board Secretary: Hu Weiwei, Securities Affairs Representative: Tian Xiaonan[15](index=15&type=chunk) - Contact Phone: **010-62882959**, Email: sbnkbod@sbnkjt.com[15](index=15&type=chunk) [Other Information](index=6&type=section&id=%E4%B8%89%E3%80%81Other%20Information) The company's contact information, disclosure channels, and registration details remained unchanged during the reporting period - The company's registered address, office address, website, and email remained unchanged during the reporting period[16](index=16&type=chunk) - Information disclosure and document storage locations remained unchanged during the reporting period[17](index=17&type=chunk) - The company's registration status remained unchanged during the reporting period[18](index=18&type=chunk) [Key Accounting Data and Financial Indicators](index=7&type=section&id=%E5%9B%9B%E3%80%81Key%20Accounting%20Data%20and%20Financial%20Indicators) This section presents key accounting data and financial indicators for the current and prior periods, showing revenue and net profit growth, but a decrease in net cash flow from operating activities Key Accounting Data and Financial Indicators Comparison | Indicator | Current Period (CNY) | Prior Period (CNY) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 827,252,437.57 | 703,791,932.88 | 17.54% | | Net Profit Attributable to Shareholders of Listed Company | 69,695,705.61 | 66,627,574.62 | 4.60% | | Net Profit Attributable to Shareholders of Listed Company Excluding Non-recurring Gains and Losses | 72,010,712.15 | 65,026,910.44 | 10.74% | | Net Cash Flow from Operating Activities | 64,769,592.22 | 82,488,469.95 | -21.48% | | Basic Earnings Per Share (CNY/share) | 0.34 | 0.32 | 6.25% | | Diluted Earnings Per Share (CNY/share) | 0.34 | 0.32 | 6.25% | | Weighted Average Return on Net Assets | 2.99% | 2.82% | 0.17% | | **Period-end Indicators Comparison** | Current Period-end (CNY) | Prior Year-end (CNY) | Period-end vs Prior Year-end Change | | Total Assets | 3,719,935,444.49 | 3,531,288,628.12 | 5.34% | | Net Assets Attributable to Shareholders of Listed Company | 2,338,094,236.80 | 2,298,441,022.18 | 1.73% | [Differences in Accounting Data Under Domestic and International Accounting Standards](index=7&type=section&id=%E4%BA%94%E3%80%81Differences%20in%20Accounting%20Data%20Under%20Domestic%20and%20International%20Accounting%20Standards) The company reports no differences in net profit and net assets between domestic and international accounting standards during the reporting period - The company reports no differences in net profit and net assets between financial reports disclosed under International Accounting Standards and Chinese Accounting Standards during the reporting period[20](index=20&type=chunk) - The company reports no differences in net profit and net assets between financial reports disclosed under overseas accounting standards and Chinese Accounting Standards during the reporting period[21](index=21&type=chunk) [Non-recurring Gains and Losses Items and Amounts](index=7&type=section&id=%E5%85%AD%E3%80%81Non-recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Non-recurring losses totaled **-2.32 million CNY**, primarily due to non-operating expenses like fines, donations, and medical dispute compensation Non-recurring Gains and Losses Items and Amounts | Item | Amount (CNY) | Description | | :--- | :--- | :--- | | Gains or losses from disposal of non-current assets (including the write-back of impairment provisions) | 1,371,703.92 | | | Government subsidies recognized in current profit or loss (excluding those closely related to normal business operations, compliant with national policies, enjoyed at fixed standards, and with a continuous impact on company profit or loss) | 815,561.47 | | | Fair value changes and disposal gains/losses from financial assets and liabilities held by non-financial enterprises, excluding effective hedging activities related to normal business operations | 309,561.42 | Income from structured deposits | | Reversal of impairment provisions for receivables subject to separate impairment testing | 1,827.69 | | | Other non-operating income and expenses | -5,956,857.37 | Mainly fines, donations, and medical dispute compensation | | Less: Income tax impact | -506,964.08 | | | Minority interest impact (after tax) | -636,232.25 | | | **Total** | **-2,315,006.54** | | [Management Discussion and Analysis](index=9&type=section&id=Management%20Discussion%20and%20Analysis) This section provides an in-depth analysis of the company's operations, financial performance, core competencies, and risk factors during the reporting period [Main Business Activities During the Reporting Period](index=9&type=section&id=%E4%B8%80%E3%80%81Main%20Business%20Activities%20During%20the%20Reporting%20Period) Sanbo Brain Hospital, a neuro-specialty medical group, operates eight hospitals across six regions, achieving revenue and net profit growth through integrated medical, educational, and research models - The company specializes in neuro-specialty, operating **8 hospitals** through an integrated medical, educational, and research and chain development model[26](index=26&type=chunk)[27](index=27&type=chunk) - During the reporting period, operating revenue was **827.25 million CNY**, a **17.54% year-on-year increase**; net profit attributable to the parent company was **69.70 million CNY**, a **4.60% year-on-year increase**[32](index=32&type=chunk) - Revenue growth is primarily due to the inclusion of Daxing Guangze in the consolidated scope, expanding business scale[32](index=32&type=chunk) - China's medical industry is driven by both policy and technological innovation, with broad development prospects for private hospitals[33](index=33&type=chunk)[38](index=38&type=chunk) [Company's Main Business and Products](index=9&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89Company%27s%20Main%20Business%20and%20Products) The company operates eight hospitals, offering a wide range of neuro-specialty and integrated medical services, including neurosurgery, neuro-intervention, and neuro-oncology - The company operates **8 hospitals**, including **5 neuro-specialty hospitals** and **3 general hospitals**[27](index=27&type=chunk) - Key diagnostic and treatment services include neurosurgery, neuro-intervention, neurology, neuro-oncology chemotherapy/radiotherapy, and neuro-critical care[27](index=27&type=chunk) - Kunming Sanbo introduced Yunnan Province's top cardiac medical team, adding cardiology to create a new multidisciplinary collaborative development model integrating heart and brain care[28](index=28&type=chunk) [Operating Model](index=10&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89Operating%20Model) The company employs a strict procurement process, standardized "360-degree service system," diverse settlement methods, and multiple patient acquisition channels - Procurement Model: Strict bidding and tendering system, utilizing internal supply chain companies Huibokang, Chongqing Xida, and Chongqing Jialele for purchasing pharmaceuticals and consumables[29](index=29&type=chunk) - Service Model: Standardized processes, providing a "**360-degree service system**" covering appointment registration, medical guidance, escort services, and post-discharge follow-up[30](index=30&type=chunk) - Settlement Model: Patient self-pay, medical insurance settlement, corporate client settlement, government procurement, commercial insurance, etc., with national pricing for medical insurance services and independent pricing for non-medical insurance services[30](index=30&type=chunk) - Patient Sources: Good reputation, medical-educational-research academic influence, introduction of local renowned experts, and multimedia brand promotion[31](index=31&type=chunk) [Analysis of Operating Performance During the Reporting Period](index=11&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89Analysis%20of%20Operating%20Performance%20During%20the%20Reporting%20Period) The company achieved revenue and net profit growth, driven by expanded consolidation scope and improved operations, despite some impact from Kunming Sanbo's new hospital relocation Operating Performance During the Reporting Period | Indicator | Current Period (million CNY) | Prior Period (million CNY) | YoY Growth | | :--- | :--- | :--- | :--- | | Operating Revenue | 82,725.24 | 70,379.19 | 17.54% | | Net Profit Attributable to Parent Company | 6,969.57 | 6,662.76 | 4.60% | - Primary reasons for revenue growth: inclusion of Daxing Guangze in consolidated statements, expanded business scale, and improved operational management and medical service levels[32](index=32&type=chunk) - Profit was affected by the relocation of Kunming Sanbo's new hospital, which added cardiology departments and upgraded hardware, now operating well[32](index=32&type=chunk) Period-end Asset and Liability Status | Indicator | Current Period-end (million CNY) | Prior Year-end (million CNY) | Change | | :--- | :--- | :--- | :--- | | Total Assets | 371,993.54 | 353,128.86 | Increase5.34% | | Net Assets Attributable to Parent Company | 233,809.42 | 229,844.10 | Increase1.73% | | Asset-Liability Ratio | 28.48% | 25.52% | Increase2.96% | - The increase in asset-liability ratio is mainly due to increased long-term borrowings and lease liabilities[32](index=32&type=chunk) [Industry Development Status](index=11&type=section&id=%EF%BC%88%E5%9B%9B%EF%BC%89Industry%20Development%20Status) China's medical industry is experiencing high-quality development driven by policy and technology, with increasing healthcare investment and broad prospects for private hospitals - The medical industry is driven by dual factors: policy (medical insurance payment reform, centralized drug procurement) and technology (AI medical large models)[33](index=33&type=chunk) - China's total health expenditure will continue to grow, influenced by rising resident incomes, an aging population, increasing chronic diseases, and the "Healthy China" strategy[35](index=35&type=chunk) - National policies encourage private medical institutions, offering broad development prospects for private hospitals to alleviate public hospital pressure and provide diversified services[37](index=37&type=chunk)[38](index=38&type=chunk) [Industry Competitive Landscape](index=13&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89Industry%20Competitive%20Landscape) Public hospitals dominate the neurosurgery sector, but Sanbo Brain Hospital, as the largest private neuro-specialty group, is enhancing its influence through flexible mechanisms and quality services - Public hospitals dominate the neurosurgery medical service industry, such as Beijing Tiantan Hospital and Shanghai Huashan Hospital[39](index=39&type=chunk) - Sanbo Brain Hospital is China's largest private neuro-specialty medical service group integrating medical care, teaching, and research[39](index=39&type=chunk) [Core Competitiveness Analysis](index=13&type=section&id=%E4%BA%8C%E3%80%81Core%20Competitiveness%20Analysis) The company's core strengths lie in its rich expert resources, leading technical capabilities, integrated medical-educational-research model, patient-centric services, extensive management experience, and established brand reputation - Rich expert resources and leading technical strength, centered around experts like Luan Guoming, with **80%** of surgeries being the most complex Level IV procedures[40](index=40&type=chunk) - Integrated "medical, educational, and research" operations, with Beijing Sanbo as an affiliated hospital of Capital Medical University, cultivating numerous master's and doctoral students, undertaking research projects, and publishing academic papers[40](index=40&type=chunk) - Prioritizing technology and service, establishing a "**360-degree service system**," with a reasonable fee structure, building a strong reputation[42](index=42&type=chunk) - Extensive management experience, achieving chain operation through restructuring, self-building, and mergers and acquisitions, with **8 hospitals** covering multiple regions[43](index=43&type=chunk) - Years of sound operation have gradually established brand advantages, gaining recognition and a good reputation in the field of neuromedicine[44](index=44&type=chunk) [Main Business Analysis](index=14&type=section&id=%E4%B8%89%E3%80%81Main%20Business%20Analysis) Operating revenue increased by **17.54%**, driven by the inclusion of Daxing Guangze, while financial expenses surged by **236.24%** due to reduced interest income and increased borrowing costs, and operating cash flow decreased by **21.48%** Year-on-Year Changes in Key Financial Data | Item | Current Period (CNY) | Prior Period (CNY) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 827,252,437.57 | 703,791,932.88 | 17.54% | Impact of Daxing Guangze's inclusion in consolidated scope | | Operating Cost | 611,132,627.11 | 527,110,071.05 | 15.94% | Impact of Daxing Guangze's inclusion in consolidated scope | | Selling Expenses | 12,408,188.20 | 10,459,751.17 | 18.63% | Increase in Henan Sanbo's business promotion expenses and Daxing Guangze's impact | | Administrative Expenses | 89,800,662.04 | 72,325,451.75 | 24.16% | Increase in employee compensation, asset amortization, and Daxing Guangze's impact | | Financial Expenses | 4,327,079.39 | -3,176,047.87 | 236.24% | Decrease in interest income due to reduced monetary funds, increase in interest expenses due to increased bank borrowings and lease liabilities | | Income Tax Expense | 30,743,222.90 | 21,229,852.24 | 44.81% | Increase in pre-tax profit of Huibokang, Chongqing Xida, Chongqing Jialele, and Daxing Guangze's impact | | Net Cash Flow from Operating Activities | 64,769,592.22 | 82,488,469.95 | -21.48% | Changes in medical insurance prepayment, increase in payments for goods and services, employee compensation, and taxes | | Net Cash Flow from Investing Activities | -204,528,984.17 | 249,826,475.75 | -181.87% | Increase in hospital construction and renovation projects, decrease in structured deposit investments and income | | Net Cash Flow from Financing Activities | 36,607,704.98 | -32,666,114.73 | 212.07% | Increase in cash inflow from bank borrowings | | Net Increase in Cash and Cash Equivalents | -103,151,686.97 | 299,648,830.97 | -134.42% | Increase in hospital construction and renovation projects, decrease in structured deposit investments and income | | Taxes and Surcharges | 4,145,791.03 | 701,498.79 | 490.99% | Increase in stamp duty and surcharges due to increased revenue, and increase in Daxing Guangze's property tax | | Fair Value Change Gains and Losses | 309,561.42 | 4,577,631.67 | -93.24% | Decrease in structured deposits | | Asset Disposal Income | 1,595,741.24 | 11,339.72 | 13,972.14% | Increase in disposal income from Kunming Sanbo's right-of-use assets | Products or Services Accounting for Over 10% of Revenue | Product or Service | Operating Revenue (CNY) | Operating Cost (CNY) | Gross Profit Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Profit Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Medical Services | 615,059,978.23 | 429,548,417.89 | 30.16% | 14.10% | 12.52% | 0.98% | | Pharmaceuticals | 207,010,862.35 | 177,203,261.55 | 14.40% | 30.06% | 26.23% | 2.60% | [Non-Core Business Analysis](index=16&type=section&id=%E5%9B%9B%E3%80%81Non-Core%20Business%20Analysis) Non-core business activities had a minor impact on total profit, primarily involving investment income, fair value changes, asset impairment, and non-operating income/expenses, with only fair value changes being sustainable Impact of Non-Core Business on Total Profit | Item | Amount (CNY) | Proportion of Total Profit | Reason for Formation | Sustainability | | :--- | :--- | :--- | :--- | :--- | | Investment Income | 1,827.69 | 0.00% | Income from recovery of receivables at the time of acquisition | No | | Fair Value Change Gains and Losses | 309,561.42 | 0.30% | Fair value change gains/losses from structured deposits held | Yes | | Asset Impairment | -99,297.91 | -0.10% | Provision for impairment of contract assets | No | | Non-operating Income | 2,374,739.52 | 2.33% | Medical liability insurance payouts and adjustments to estimated liabilities | No | | Non-operating Expenses | 8,555,634.21 | 8.38% | Donations, medical dispute compensation, losses from destruction/scrapping of non-current assets, etc | No | | Other Income | 1,618,305.49 | 1.59% | Government subsidies received, individual income tax refunds | No | | Asset Disposal Income | 1,595,741.24 | 1.56% | Net gain from disposal of right-of-use assets | No | [Analysis of Assets and Liabilities](index=16&type=section&id=%E4%BA%94%E3%80%81Analysis%20of%20Assets%20and%20Liabilities) Total assets increased by **5.34%** to **3.72 billion CNY**, and net assets attributable to the parent company grew by **1.73%** to **2.34 billion CNY**, with significant changes in fixed assets, right-of-use assets, long-term borrowings, and lease liabilities - The company's total assets at the end of the reporting period were **3.72 billion CNY**, an increase of **5.34%** from the prior year-end; net assets attributable to the parent company were **2.34 billion CNY**, an increase of **1.73%** from the prior year-end[19](index=19&type=chunk) [1、Significant Changes in Asset Composition](index=16&type=section&id=1%E3%80%81Significant%20Changes%20in%20Asset%20Composition) Significant changes in asset composition include substantial increases in contract assets, fixed assets, right-of-use assets, long-term borrowings, and lease liabilities, while monetary funds and employee compensation decreased Significant Changes in Asset Composition | Item | Current Period-end Amount (CNY) | Proportion of Total Assets | Prior Year-end Amount (CNY) | Proportion of Total Assets | Proportion Change | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Monetary Funds | 517,289,042.18 | 13.91% | 708,348,100.12 | 20.06% | -6.15% | | | Contract Assets | 2,230,134.33 | 0.06% | 343,474.13 | 0.01% | 0.05% | Increased by **549.29%**, mainly due to increased medical insurance fund quality assurance deposits by Henan Sanbo, Fujian Sanbo, and Luoyang Sanbo | | Fixed Assets | 920,565,871.66 | 24.75% | 606,595,212.30 | 17.18% | 7.57% | Increased by **51.76%**, mainly due to Kunming Sanbo's new hospital project being transferred from construction in progress to fixed assets | | Right-of-Use Assets | 184,304,157.92 | 4.95% | 121,982,362.73 | 3.45% | 1.50% | Increased by **51.09%**, mainly due to the expiration of original lease contracts for Chongqing Sanbo Chang'an, Chongqing Sanbo Jiangling, and new leased area for Henan Sanbo | | Long-term Borrowings | 198,990,294.89 | 5.35% | 135,775,842.49 | 3.84% | 1.51% | Increased by **46.56%**, mainly due to increased bank borrowings by Kunming Sanbo, Xi'an Sanbo, and Kunming Haoyuan | | Lease Liabilities | 174,255,760.92 | 4.68% | 107,232,700.93 | 3.04% | 1.64% | Increased by **62.50%**, mainly due to the expiration of original lease contracts for Chongqing Sanbo Chang'an, Chongqing Sanbo Jiangling, and new leased area for Henan Sanbo | | Employee Compensation Payable | 69,701,663.01 | 1.87% | 120,558,206.22 | 3.41% | -1.54% | Decreased by **42.18%**, mainly due to payment of prior year's annual bonus during the current reporting period | | Other Payables | 65,875,199.55 | 1.77% | 28,238,402.98 | 0.80% | 0.97% | Increased by **133.28%**, mainly due to increased cash dividends payable during the current reporting period | [2、Major Overseas Assets](index=18&type=section&id=2%E3%80%81Major%20Overseas%20Assets) The company had no major overseas assets during the reporting period - The company had no major overseas assets during the reporting period[56](index=56&type=chunk) [3、Assets and Liabilities Measured at Fair Value](index=18&type=section&id=3%E3%80%81Assets%20and%20Liabilities%20Measured%20at%20Fair%20Value) At the end of the reporting period, the company's financial assets measured at fair value totaled **52.24 million CNY**, primarily consisting of trading financial assets Financial Assets Measured at Fair Value | Item | Beginning Balance (CNY) | Fair Value Change Gains and Losses for the Period (CNY) | Amount Purchased During the Period (CNY) | Amount Sold During the Period (CNY) | Ending Balance (CNY) | | :--- | :--- | :--- | :--- | :--- | :--- | | 1. Trading financial assets (excluding derivative financial assets) | 50,134,972.68 | 309,561.42 | 152,200,000.00 | 150,000,000.00 | 52,236,065.57 | | Subtotal of Financial Assets | 50,134,972.68 | 309,561.42 | 152,200,000.00 | 150,000,000.00 | 52,236,065.57 | | Total Above | 50,134,972.68 | 309,561.42 | 152,200,000.00 | 150,000,000.00 | 52,236,065.57 | [4、Asset Rights Restricted as of the End of the Reporting Period](index=18&type=section&id=4%E3%80%81Asset%20Rights%20Restricted%20as%20of%20the%20End%20of%20the%20Reporting%20Period) As of the end of the reporting period, assets totaling **1.13 billion CNY** were restricted, primarily fixed assets, intangible assets, and construction in progress, serving as collateral for loans Asset Rights Restricted | Item | Book Balance (CNY) | Book Value (CNY) | Type of Restriction | Restriction Details | | :--- | :--- | :--- | :--- | :--- | | Fixed Assets | 233,611,480.37 | 233,230,343.50 | Mortgage | Fixed assets pledged as collateral for loans | | Intangible Assets | 496,553,711.23 | 441,124,354.94 | Mortgage | Land use rights pledged as collateral for loans | | Construction in Progress | 397,210,874.77 | 397,210,874.77 | Mortgage | Construction in progress pledged as collateral for loans | | **Total** | **1,127,376,066.37** | **1,071,565,573.21** | | | [Investment Analysis](index=18&type=section&id=%E5%85%AD%E3%80%81Investment%20Analysis) Total investments decreased by **65.58%** to **502.49 million CNY**, with significant non-equity investments in hospital construction projects and a **85.77%** utilization rate of raised funds Investment Amount During the Reporting Period | Indicator | Investment Amount Current Period (CNY) | Investment Amount Prior Period (CNY) | Change Rate | | :--- | :--- | :--- | :--- | | Total Investment | 502,489,340.33 | 1,459,891,512.02 | -65.58% | - The overall utilization rate of raised funds is **85.77%**, with a cumulative use of **910.53 million CNY**[67](index=67&type=chunk) - **300 million CNY** of over-raised funds has been used for permanent replenishment of working capital and capital injection into wholly-owned subsidiaries for external investment and equity acquisition[69](index=69&type=chunk)[70](index=70&type=chunk) [1、Overall Situation](index=18&type=section&id=1%E3%80%81Overall%20Situation) The company's total investment for the reporting period was **502.49 million CNY**, a significant decrease of **65.58%** compared to the prior period Investment Amount During the Reporting Period | Indicator | Investment Amount Current Period (CNY) | Investment Amount Prior Period (CNY) | Change Rate | | :--- | :--- | :--- | :--- | | Total Investment | 502,489,340.33 | 1,459,891,512.02 | -65.58% | [2、Significant Equity Investments Acquired During the Reporting Period](index=19&type=section&id=2%E3%80%81Significant%20Equity%20Investments%20Acquired%20During%20the%20Reporting%20Period) The company made no significant equity investments during the reporting period - The company made no significant equity investments during the reporting period[61](index=61&type=chunk) [3、Significant Non-Equity Investments in Progress During the Reporting Period](index=19&type=section&id=3%E3%80%81Significant%20Non-Equity%20Investments%20in%20Progress%20During%20the%20Reporting%20Period) The company is undertaking major non-equity investments in several hospital construction projects, including Beijing, Xi'an, Hunan, and Kunming, with varying progress and some economic environment impacts Significant Non-Equity Investments in Progress | Project Name | Investment Method | Industry Involved in Investment Project | Amount Invested During Current Period (CNY) | Cumulative Actual Investment Amount as of Period-end (CNY) | Project Progress | Cumulative Income Achieved as of Period-end (CNY) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Capital Medical University Sanbo Brain Hospital Construction Project | Self-built | Medical Services | 87,670,051.18 | 778,808,959.08 | 66.58% | 0.00 | | Xi'an Sanbo Brain Hospital Construction Project | Self-built | Medical Services | 39,952,985.83 | 120,332,419.51 | 80.22% | 0.00 | | Hunan Sanbo Brain Hospital Construction Project | Self-built | Medical Services | 42,430,883.05 | 310,752,396.88 | 43.06% | 0.00 | | Kunming Sanbo Brain Hospital New Campus Construction Project | Self-built | Medical Services | 61,149,005.52 | 344,052,878.26 | 65.97% | -888.42 | - Hunan Sanbo Brain Hospital project and Kunming Sanbo new campus project experienced changes in progress and performance due to economic environment and relocation impacts[62](index=62&type=chunk) [4、Financial Assets Measured at Fair Value](index=19&type=section&id=4%E3%80%81Financial%20Assets%20Measured%20at%20Fair%20Value) The company's financial assets measured at fair value primarily consist of structured deposits, totaling **52.24 million CNY** at period-end, with **0.31 million CNY** in fair value change gains for the period Financial Assets Measured at Fair Value | Asset Category | Initial Investment Cost (CNY) | Fair Value Change Gains and Losses for the Period (CNY) | Amount Purchased During the Reporting Period (CNY) | Amount Sold During the Reporting Period (CNY) | Cumulative Investment Income (CNY) | Ending Balance (CNY) | Source of Funds | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Other (Own Funds) | | 86,824.70 | 52,200,000.00 | 50,000,000.00 | 86,824.70 | 2,200,000.00 | Own Funds | | Other (Raised Funds) | 50,000,000.00 | 222,736.72 | 100,000,000.00 | 100,000,000.00 | 357,709.40 | 50,036,065.57 | Raised Funds | | **Total** | **50,000,000.00** | **309,561.42** | **152,200,000.00** | **150,000,000.00** | **444,534.10** | **52,236,065.57** | | [5、Use of Raised Funds](index=20&type=section&id=5%E3%80%81Use%20of%20Raised%20Funds) The company's initial public offering raised **1.06 billion CNY**, with **85.77%** utilized, including over-raised funds for working capital and subsidiary investments, and project changes and delays Overall Use of Raised Funds | Year of Raising | Method of Raising | Total Raised Funds (million CNY) | Net Raised Funds (million CNY) | Total Raised Funds Used in Current Period (million CNY) | Cumulative Total Raised Funds Used (million CNY) | Utilization Rate of Raised Funds at Period-end | Cumulative Amount of Raised Funds with Changed Use (million CNY) | Proportion of Cumulative Raised Funds with Changed Use | Total Unused Raised Funds (million CNY) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | 2023 | Initial Public Offering | 117,254.18 | 106,163.91 | 8,824.86 | 91,052.99 | 85.77% | 30,000 | 28.26% | 15,110.92 | - Over-raised funds of **561.64 million CNY** have been fully utilized, including **320 million CNY** for permanent replenishment of working capital in two instances, and **420 million CNY** for capital injection into wholly-owned subsidiaries for external investment and equity acquisition[69](index=69&type=chunk)[70](index=70&type=chunk)[74](index=74&type=chunk) - The unused raised funds of **300 million CNY** from the original "Hunan Sanbo Brain Hospital Project" have been reallocated to the "Capital Medical University Sanbo Brain Hospital Construction Project"[73](index=73&type=chunk)[76](index=76&type=chunk) - The "Sanbo Brain Hospital Informationization Construction Project" has slowed down and been delayed, not generating direct economic benefits but enhancing informationization capabilities and management levels[73](index=73&type=chunk) [Significant Asset and Equity Sales](index=25&type=section&id=%E4%B8%83%E3%80%81Significant%20Asset%20and%20Equity%20Sales) The company did not sell any significant assets or equity during the reporting period - The company did not sell any significant assets during the reporting period[80](index=80&type=chunk) - The company did not sell any significant equity during the reporting period[81](index=81&type=chunk) [Analysis of Major Holding and Participating Companies](index=25&type=section&id=%E5%85%AB%E3%80%81Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) The company's major subsidiaries include several hospitals and medical supply companies, with Kunming Sanbo Brain Hospital and Sichuan Daxing Guangze Medical Investment Management Co, Ltd reporting negative net profits Financial Data of Major Subsidiaries | Company Name | Company Type | Main Business | Registered Capital (million CNY) | Total Assets (million CNY) | Net Assets (million CNY) | Operating Revenue (million CNY) | Operating Profit (million CNY) | Net Profit (million CNY) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Beijing Sanbo Brain Hospital Co, Ltd | Subsidiary | Medical Services | 52,650 | 107,626.83 | 81,219.98 | 26,156.86 | 4,659.43 | 3,269.70 | | Chongqing Sanbo Chang'an Hospital Co, Ltd | Subsidiary | Medical Services | 4,000 | 26,732.28 | 15,611.00 | 15,103.06 | 1,614.89 | 1,419.11 | | Chongqing Sanbo Jiangling Hospital Co, Ltd | Subsidiary | Medical Services | 4,000 | 25,685.10 | 17,086.89 | 10,658.72 | 1,563.89 | 1,356.65 | | Luoyang Wuyiyi Sanbo Brain Hospital Co, Ltd | Subsidiary | Medical Services | 7,000 | 11,110.73 | 9,056.99 | 4,656.91 | 1,134.21 | 848.10 | | Kunming Sanbo Brain Hospital Co, Ltd | Subsidiary | Medical Services | 6,270 | 13,461.75 | -1,486.78 | 2,097.50 | -796.06 | -888.42 | | Beijing Huibokang Medical Device Management Co, Ltd | Subsidiary | Medical Device Management | 100 | 2,515.27 | 1,497.39 | 3,168.02 | 965.82 | 723.07 | | Chongqing Xida Pharmaceutical Co, Ltd | Subsidiary | Pharmaceuticals, Medical Device Management | 2,000 | 8,609.51 | 7,103.63 | 9,639.80 | 2,979.99 | 2,219.91 | | Sichuan Daxing Guangze Medical Investment Management Co, Ltd | Subsidiary | Medical Services | 29,608.2474 | 41,015.35 | 30,277.44 | 14,654.45 | -46.48 | -394.87 | - The company neither acquired nor disposed of any subsidiaries during the reporting period[83](index=83&type=chunk) [Structured Entities Controlled by the Company](index=26&type=section&id=%E4%B9%9D%E3%80%81Structured%20Entities%20Controlled%20by%20the%20Company) The company did not control any structured entities during the reporting period - The company did not control any structured entities during the reporting period[84](index=84&type=chunk) [Risks Faced by the Company and Countermeasures](index=26&type=section&id=%E5%8D%81%E3%80%81Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company faces risks from regulatory changes, talent shortages, supply chain disruptions, and management challenges due to expansion, addressed by policy adaptation, talent development, strict procurement, and group-level control - The company faces risks from changes in industry regulatory policies: tightening policies or failure to meet regulatory requirements may impact operations[84](index=84&type=chunk) - The company faces risks of professional and technical talent shortages: increased demand for high-level medical staff and talent loss affect development[84](index=84&type=chunk) - The company faces risks in raw material supply: quality defects or supply interruptions of pharmaceuticals and consumables affect diagnosis, treatment, and reputation[86](index=86&type=chunk) - The company faces management risks after scale expansion: chain operations impose higher requirements on medical quality, human resources, and financial management[87](index=87&type=chunk) - Countermeasures for talent shortage: multi-faceted talent cultivation and introduction, collaboration with local expert teams, and formulation of talent allocation plans[85](index=85&type=chunk) - Countermeasures for scale expansion management: establishing a listed company management control and subsidiary operational entity structure, achieving group-level control through management, quality, and operational layer assessments[88](index=88&type=chunk)[89](index=89&type=chunk) [Registration Form for Research, Communication, Interview, and Other Activities During the Reporting Period](index=28&type=section&id=%E5%8D%81%E4%B8%80%E3%80%81Registration%20Form%20for%20Research%2C%20Communication%2C%20Interview%2C%20and%20Other%20Activities%20During%20the%20Reporting%20Period) During the reporting period, the company held an earnings briefing via Panorama Network and engaged in phone discussions with individual investors on various business and strategic topics - An earnings briefing was held on **May 12, 2025**, via Panorama Network's "Investor Relations Interactive Platform"[90](index=90&type=chunk) - During the reporting period, individual investors were engaged via phone discussions on main business, expansion plans, new hospital construction, share repurchases, medical insurance policies, and brain-computer interface layout[90](index=90&type=chunk) [Formulation and Implementation of Market Value Management System and Valuation Enhancement Plan](index=28&type=section&id=%E5%8D%81%E4%BA%8C%E3%80%81Formulation%20and%20Implementation%20of%20Market%20Value%20Management%20System%20and%20Valuation%20Enhancement%20Plan) The company has not disclosed a market value management system or a valuation enhancement plan - The company has not formulated a market value management system[91](index=91&type=chunk) - The company has not disclosed a valuation enhancement plan[91](index=91&type=chunk) [Implementation of the "Dual Improvement in Quality and Returns" Action Plan](index=28&type=section&id=%E5%8D%81%E4%B8%89%E3%80%81Implementation%20of%20the%20%22Dual%20Improvement%20in%20Quality%20and%20Returns%22%20Action%20Plan) The company has not disclosed an announcement regarding the "Dual Improvement in Quality and Returns" action plan - The company has not disclosed an announcement regarding the "Dual Improvement in Quality and Returns" action plan[91](index=91&type=chunk) [Corporate Governance, Environment, and Society](index=29&type=section&id=Corporate%20Governance%2C%20Environment%2C%20and%20Society) This section details changes in the company's senior management, profit distribution plans, environmental disclosures, and social responsibility initiatives during the reporting period [Changes in Directors, Supervisors, and Senior Management](index=29&type=section&id=%E4%B8%80%E3%80%81Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, Zhang Yang was relieved of his General Manager duties but remains Chairman, and Xu Xiangying was appointed as the new General Manager - Zhang Yang was relieved of his General Manager position on **March 4, 2025**, but continues to serve as Chairman[93](index=93&type=chunk) - Xu Xiangying was appointed as General Manager on **March 4, 2025**[93](index=93&type=chunk) [Profit Distribution and Capital Reserve Conversion to Share Capital During the Reporting Period](index=29&type=section&id=%E4%BA%8C%E3%80%81Profit%20Distribution%20and%20Capital%20Reserve%20Conversion%20to%20Share%20Capital%20During%20the%20Reporting%20Period) The company plans no interim cash dividends, bonus shares, or capital reserve conversions to share capital for the semi-annual period - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the semi-annual period[94](index=94&type=chunk) [Implementation of Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=29&type=section&id=%E4%B8%89%E3%80%81Implementation%20of%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%2C%20or%20Other%20Employee%20Incentive%20Measures) The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures in place during the reporting period - The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period[95](index=95&type=chunk) [Environmental Information Disclosure](index=29&type=section&id=%E5%9B%9B%E3%80%81Environmental%20Information%20Disclosure) The company and its subsidiary, Chengdu Sanbo Dongli Hospital Co, Ltd, are listed as legally required environmental information disclosure enterprises and have publicly released their environmental reports - The company and its major subsidiary, Chengdu Sanbo Dongli Hospital Co, Ltd, are included in the list of enterprises required to disclose environmental information by law[96](index=96&type=chunk) - Chengdu Sanbo Dongli Hospital Co, Ltd has publicly disclosed its environmental information report[96](index=96&type=chunk) [Social Responsibility](index=29&type=section&id=%E4%BA%94%E3%80%81Social%20Responsibility) The company prioritizes sustainable development, legal compliance, and balancing economic and social benefits, actively protecting stakeholder rights and engaging in extensive social welfare initiatives - Protection of shareholder and creditor rights: improving corporate governance structure and internal control systems, disclosing information truthfully, accurately, completely, timely, and fairly, and strengthening investor communication[97](index=97&type=chunk) - Protection of employee rights: strictly enforcing labor laws and regulations, improving employee management systems, and providing career development paths and academic platforms[98](index=98&type=chunk) - Protection of supplier and customer rights: establishing a sound procurement system, adhering to fair and just principles; providing a "**360-degree service system**" for patients, ensuring a "patient-centered" service philosophy[99](index=99&type=chunk) - Social welfare: actively undertaking social responsibility, participating in community lectures and public assistance projects (such as "Loving Mothers," "Melting the Frozen Heart"), cumulatively funding poor patients over **10 million CNY**[100](index=100&type=chunk) - Deeply participating in the National Health Commission's "Heart-to-Heart Project" health assistance activities, promoting the downward transfer of quality medical resources to Inner Mongolia, Jiangxi, Sichuan, and other regions[101](index=101&type=chunk) [Significant Matters](index=31&type=section&id=Significant%20Matters) This section covers the company's commitments, related party transactions, litigation, penalties, and other significant events during the reporting period [Commitments Fulfilled and Overdue Unfulfilled by Controlling Shareholder, Shareholders, Related Parties, Acquirers, and the Company During and as of the End of the Reporting Period](index=31&type=section&id=%E4%B8%80%E3%80%81Commitments%20Fulfilled%20and%20Overdue%20Unfulfilled%20by%20Controlling%20Shareholder%2C%20Shareholders%2C%20Related%20Parties%2C%20Acquirers%2C%20and%20the%20Company%20During%20and%20as%20of%20the%20End%20of%20the%20Reporting%20Period) The company reports no commitments fulfilled or overdue unfulfilled by relevant parties during or as of the end of the reporting period - The company reports no commitments fulfilled or overdue unfulfilled by relevant parties during the reporting period[104](index=104&type=chunk) [Non-Operating Funds Occupied by Controlling Shareholder and Other Related Parties from the Listed Company](index=31&type=section&id=%E4%BA%8C%E3%80%81Non-Operating%20Funds%20Occupied%20by%20Controlling%20Shareholder%20and%20Other%20Related%20Parties%20from%20the%20Listed%20Company) The company reports no non-operating funds occupied by controlling shareholders or other related parties during the reporting period - The company reports no non-operating funds occupied by controlling shareholders or other related parties during the reporting period[105](index=105&type=chunk) [Illegal External Guarantees](index=31&type=section&id=%E4%B8%89%E3%80%81Illegal%20External%20Guarantees) The company had no illegal external guarantees during the reporting period - The company had no illegal external guarantees during the reporting period[106](index=106&type=chunk) [Appointment and Dismissal of Accounting Firms](index=31&type=section&id=%E5%9B%9B%E3%80%81Appointment%20and%20Dismissal%20of%20Accounting%20Firms) The company's semi-annual report was unaudited - The company's semi-annual report was unaudited[107](index=107&type=chunk) [Board of Directors, Supervisory Board, and Audit Committee's Explanation of the Accounting Firm's "Non-Standard Audit Report" for the Current Period](index=31&type=section&id=%E4%BA%94%E3%80%81Board%20of%20Directors%2C%20Supervisory%20Board%2C%20and%20Audit%20Committee%27s%20Explanation%20of%20the%20Accounting%20Firm%27s%20%22Non-Standard%20Audit%20Report%22%20for%20the%20Current%20Period) The company reports no explanations from the board, supervisory board, or audit committee regarding a "non-standard audit report" for the current period - The company reports no explanations regarding a "non-standard audit report" from the accounting firm for the current period[108](index=108&type=chunk) [Board of Directors' Explanation of the Prior Year's "Non-Standard Audit Report" Related Matters](index=31&type=section&id=%E5%85%AD%E3%80%81Board%20of%20Directors%27%20Explanation%20of%20the%20Prior%20Year%27s%20%22Non-Standard%20Audit%20Report%22%20Related%20Matters) The company reports no explanations from the board of directors regarding the prior year's "non-standard audit report" related matters - The company reports no explanations regarding the prior year's "non-standard audit report" related matters[108](index=108&type=chunk) [Bankruptcy and Reorganization Related Matters](index=31&type=section&id=%E4%B8%83%E3%80%81Bankruptcy%20and%20Reorganization%20Related%20Matters) The company had no bankruptcy or reorganization related matters during the reporting period - The company had no bankruptcy or reorganization related matters during the reporting period[108](index=108&type=chunk) [Litigation Matters](index=31&type=section&id=%E5%85%AB%E3%80%81Litigation%20Matters) The company had no major litigation or arbitration during the reporting period, but other lawsuits, including medical liability and contract disputes, were ongoing or concluded, with no significant impact on operations - The company had no major litigation or arbitration matters during the reporting period[109](index=109&type=chunk) Other Litigation Matters | Basic Information on Litigation (Arbitration) | Amount Involved (million CNY) | Whether Estimated Liabilities Formed | Litigation (Arbitration) Progress | Litigation (Arbitration) Outcome and Impact | Execution Status of Litigation (Arbitration) Judgment | | :--- | :--- | :--- | :--- | :--- | :--- | | Medical Liability Damage Disputes | 10.53 | The company has made corresponding provisions for estimated liabilities for some cases in accordance with accounting standards | Some cases have been closed and executed, involving an amount of **0.51 million CNY**. Other cases are in first instance or awaiting appraisal procedures | Will not have a significant impact on the company's operating results | The executed amount involved is **0.51 million CNY** | | Contract Disputes | 23.18 | The company has made corresponding provisions for estimated liabilities in accordance with accounting standards | The second instance judgment has become effective | The second instance rejected the appeal and upheld the original judgment, meaning the company must pay the plaintiff **5.64 million CNY** in liquidated damages and bear **0.04 million CNY** in case acceptance fees. This had a certain positive impact on the company's 2024 performance | Executed | [Penalties and Rectification](index=32&type=section&id=%E4%B9%9D%E3%80%81Penalties%20and%20Rectification) The company had no penalties or rectification situations during the reporting period - The company had no penalties or rectification situations during the reporting period[111](index=111&type=chunk) [Integrity Status of the Company, its Controlling Shareholder, and Actual Controller](index=32&type=section&id=%E5%8D%81%E3%80%81Integrity%20Status%20of%20the%20Company%2C%20its%20Controlling%20Shareholder%2C%20and%20Actual%20Controller) The company reports no integrity issues concerning itself, its controlling shareholder, or actual controller during the reporting period - The company reports no integrity issues concerning itself, its controlling shareholder, or actual controller during the reporting period[112](index=112&type=chunk) [Significant Related Party Transactions](index=32&type=section&id=%E5%8D%81%E4%B8%80%E3%80%81Significant%20Related%20Party%20Transactions) The company had no significant related party transactions, including daily operations, asset/equity sales, joint investments, or financial dealings, during the reporting period - The company had no related party transactions related to daily operations during the reporting period[112](index=112&type=chunk) - The company had no related party transactions involving asset or equity acquisitions or sales during the reporting period[113](index=113&type=chunk) - The company had no related party transactions involving joint external investments during the reporting period[114](index=114&type=chunk) - The company had no related party creditor-debtor transactions during the reporting period[115](index=115&type=chunk) - The company had no deposits, loans, credit lines, or other financial business with related financial companies[116](index=116&type=chunk) - The financial companies controlled by the company had no deposits, loans, credit lines, or other financial business with related parties[117](index=117&type=chunk) - The company had no other significant related party transactions during the reporting period[118](index=118&type=chunk) [Significant Contracts and Their Performance](index=33&type=section&id=%E5%8D%81%E4%BA%8C%E3%80%81Significant%20Contracts%20and%20Their%20Performance) The company had no trust or contracting arrangements, but engaged in various property leases and provided external guarantees totaling **8.89%** of net assets for subsidiary bank loans, with no other major contracts - The company had no trust arrangements during the reporting period[119](index=119&type=chunk) - The company had no contracting arrangements during the reporting period[120](index=120&type=chunk) - The company has multiple property lease contracts, primarily for medical operations and office use[121](index=121&type=chunk)[122](index=122&type=chunk) - Lease contracts for Chongqing Sanbo Chang'an, Chongqing Sanbo Jiangling, and Luoyang Wuyiyi Sanbo Brain Hospital are in the third stage of price negotiation, currently provisionally set at the first stage price[564](index=564&type=chunk)[565](index=565&type=chunk)[566](index=566&type=chunk) - The total external guarantees by the company and its subsidiaries amount to **207.77 million CNY**, accounting for **8.89%** of the company's net assets[126](index=126&type=chunk) - Primarily providing joint liability guarantees for subsidiary bank borrowings, including construction project loans for Kunming Sanbo, Kunming Haoyuan, Beijing Sanbo, and Xi'an Sanbo[124](index=124&type=chunk)[131](index=131&type=chunk)[132](index=132&type=chunk) - The company had no significant contracts related to daily operations during the reporting period[128](index=128&type=chunk) - The company had no other significant contracts during the reporting period[129](index=129&type=chunk) [Explanation of Other Significant Matters](index=37&type=section&id=%E5%8D%81%E4%B8%89%E3%80%81Explanation%20of%20Other%20Significant%20Matters) The company reports no other significant matters requiring explanation during the reporting period - The company reports no other significant matters requiring explanation during the reporting period[130](index=130&type=chunk) [Significant Matters of Company Subsidiaries](index=37&type=section&id=%E5%8D%81%E5%9B%9B%E3%80%81Significant%20Matters%20of%20Company%20Subsidiaries) The company reports no significant matters concerning its subsidiaries during the reporting period - The company reports no significant matters concerning its subsidiaries during the reporting period[131](index=131&type=chunk) [Share Changes and Shareholder Information](index=38&type=section&id=Share%20Changes%20and%20Shareholder%20Information) This section details the company's share capital structure, shareholder numbers, top shareholders, and any changes in shareholdings or control during the reporting period [Share Change Status](index=38&type=section&id=%E4%B8%80%E3%80%81Share%20Change%20Status) The company's total share capital remained unchanged at **205.99 million shares**, with **1.46%** repurchased, and no other share changes during the reporting period Share Change Status | Item | Quantity (shares) | Proportion | | :--- | :--- | :--- | | I. Restricted Shares | 45,041,295 | 21.87% | | 3. Other domestic shares | 45,041,295 | 21.87% | | Of which: shares held by domestic natural persons | 45,041,295 | 21.87% | | II. Unrestricted Shares | 160,945,692 | 78.13% | | 1. RMB ordinary shares | 160,945,692 | 78.13% | | **III. Total Shares** | **205,986,987** | **100.00%** | - The company completed its share repurchase plan on **April 16, 2025**, cumulatively repurchasing **2,997,183 shares**, accounting for **1.46%** of the company's total share capital[135](index=135&type=chunk) - The total repurchase amount was **104.19 million CNY**, with a highest transaction price of **35.06 CNY/share** and a lowest transaction price of **34.01 CNY/share**[135](index=135&type=chunk) [Securities Issuance and Listing](index=39&type=section&id=%E4%BA%8C%E3%80%81Securities%20Issuance%20and%20Listing) The company had no securities issuance or listing activities during the reporting period - The company had no securities issuance or listing activities during the reporting period[138](index=138&type=chunk) [Number of Shareholders and Shareholding Status](index=39&type=section&id=%E4%B8%89%E3%80%81Number%20of%20Shareholders%20and%20Shareholding%20Status) At period-end, the company had **43,206** ordinary shareholders, with TBP 3Doctors (HK) Limited as the largest shareholder, and the actual controllers acting in concert - Total number of ordinary shareholders at period-end: **43,206**[139](index=139&type=chunk) Shareholding Status of Shareholders Holding 5% or More or Top 10 Shareholders | Shareholder Name | Shareholder Nature | Shareholding Proportion | Number of Shares Held at Period-end (shares) | Changes in Shareholding During the Reporting Period (shares) | Number of Restricted Shares Held (shares) | Number of Unrestricted Shares Held (shares) | Share Status | Quantity (shares) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | TBP 3Doctors (HK) Limited | Overseas Legal Person | 15.16% | 31,235,425 | -1,094,600 | 0 | 31,235,425 | N/A | 0 | | Zhang Yang | Domestic Natural Person | 10.59% | 21,815,703 | 0 | 21,815,703 | 0 | N/A | 0 | | Yu Chunjiang | Domestic Natural Person | 4.17% | 8,592,376 | 0 | 8,592,376 | 0 | N/A | 0 | | Luan Guoming | Domestic Natural Person | 4.17% | 8,592,376 | 0 | 8,592,376 | 0 | N/A | 0 | | Shi Xiang'en | Domestic Natural Person | 2.93% | 6,040,840 | 0 | 6,040,840 | 0 | N/A | 0 | | Bank of China Co, Ltd - Hwabao CSI Medical ETF | Other | 2.33% | 4,804,950 | 4,804,950 | 0 | 4,804,950 | N/A | 0 | | Lin Ruiyan | Domestic Natural Person | 1.80% | 3,713,647 | -1,158,271 | 0 | 3,713,647 | N/A | 0 | | Yang Hongpeng | Overseas Natural Person | 1.78% | 3,665,633 | 0 | 0 | 3,665,633 | Frozen | 3,665,633 | | Taikang Life Insurance Co, Ltd - Traditional - Ordinary Insurance Product-019L-CT001 Shenzhen | Other | 0.90% | 1,857,053 | -1,963,200 | 0 | 1,857,053 | N/A | 0 | | GF Xinde Investment Management Co, Ltd - GF Xinde Zhongheng Huijin (Longyan) Equity Investment Partnership (Limited Partnership) | Other | 0.73% | 1,501,436 | -1,612,720 | 0 | 1,501,436 | N/A | 0 | - Zhang Yang, Yu Chunjiang, Shi Xiang'en, and Luan Guoming are persons acting in concert, jointly constituting the company's controlling shareholders and actual controllers[140](index=140&type=chunk) - The company's dedicated share repurchase securities account held **2,997,183 ordinary shares** at the end of the reporting period, accounting for **1.46%** of the company's total share capital[140](index=140&type=chunk) [Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=41&type=section&id=%E5%9B%9B%E3%80%81Changes%20in%20Shareholdings%20of%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) The shareholdings of the company's directors, supervisors, and senior management remained unchanged during the reporting period - The shareholdings of the company's directors, supervisors, and senior management remained unchanged during the reporting period[142](index=142&type=chunk) [Changes in Controlling Shareholder or Actual Controller](index=41&type=section&id=%E4%BA%94%E3%80%81Changes%20in%20Controlling%20Shareholder%20or%20Actual%20Controller) The company's controlling shareholder and actual controller remained unchanged during the reporting period - The company's controlling shareholder remained unchanged during the reporting period[143](index=143&type=chunk) - The company's actual controller remained unchanged during the reporting period[143](index=143&type=chunk) [Preferred Share Related Matters](index=41&type=section&id=%E5%85%AD%E3%80%81Preferred%20Share%20Related%20Matters) The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period[144](index=144&type=chunk) [Bond Related Matters](index=42&type=section&id=Bond%20Related%20Matters) The company had no bond-related matters during the reporting period [Bond Related Matters](index=42&type=section&id=%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) The company had no bond-related matters during the reporting period - The company had no bond-related matters during the reporting period[146](index=146&type=chunk) [Financial Report](index=43&type=section&id=Financial%20Report) This section presents the company's unaudited semi-annual financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in equity, along with detailed notes [Audit Report](index=43&type=section&id=%E4%B8%80%E3%80%81Audit%20Report) The company's semi-annual financial report was unaudited - The company's semi-annual financial report was unaudited[148](index=148&type=chunk) [Financial Statements](index=43&type=section&id=%E4%BA%8C%E3%80%81Financial%20Statements) This section provides the company's 2025 semi-annual consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in equity - Consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in equity are provided[149](index=149&type=chunk)[153](index=153&type=chunk)[157](index=157&type=chunk)[161](index=161&type=chunk)[165](index=165&type=chunk)[168](index=168&type=chunk)[171](index=171&type=chunk)[180](index=180&type=chunk) [1、Consolidated Balance Sheet](index=43&type=section&id=1%E3%80%81Consolidated%20Balance%20Sheet) As of June 30, 2025, the company's consolidated total assets were **3.72 billion CNY**, with total liabilities of **1.06 billion CNY** and total owner's equity of **2.66 billion CNY** Key Data from Consolidated Balance Sheet | Item | Period-end Balance (CNY) | Beginning Balance (CNY) | | :--- | :--- | :--- | | Total Assets | 3,719,935,444.49 | 3,531,288,628.12 | | Total Current Assets | 802,578,865.20 | 980,464,070.04 | | Total Non-current Assets | 2,917,356,579.29 | 2,550,824,558.08 | | Total Liabilities | 1,059,508,520.99 | 901,385,348.22 | | Total Owner's Equity | 2,660,426,923.50 | 2,629,903,279.90 | [2、Parent Company Balance Sheet](index=45&type=section&id=2%E3%80%81Parent%20Company%20Balance%20Sheet) As of June 30, 2025, the parent company's total assets were **2.07 billion CNY**, with total liabilities of **52.09 million CNY** and total owner's equity of **2.02 billion CNY** Key Data from Parent Company Balance Sheet | Item | Period-end Balance (CNY) | Beginning Balance (CNY) | | :--- | :--- | :--- | | Total Assets | 2,069,055,339.79 | 2,023,150,951.44 | | Total Current Assets | 466,149,591.48 | 422,199,447.10 | | Total Non-current Assets | 1,602,905,748.31 | 1,600,951,504.34 | | Total Liabilities | 52,086,563.22 | 22,007,954.48 | | Total Owner's Equity | 2,016,968,776.57 | 2,001,142,996.96 | [3、Consolidated Income Statement](index=47&type=section&id=3%E3%80%81Consolidated%20Income%20Statement) For the first half of 2025, consolidated operating revenue was **827.25 million CNY**, with net profit of **71.35 million CNY**, and basic and diluted earnings per share of **0.34 CNY/share** Key Data from Consolidated Income Statement | Item | H1 2025 (CNY) | H1 2024 (CNY) | | :--- | :--- | :--- | | Total Operating Revenue | 827,252,437.57 | 703,791,932.88 | | Total Operating Cost | 721,814,347.77 | 607,420,724.89 | | Operating Profit | 108,275,252.19 | 103,085,757.71 | | Total Profit | 102,094,357.50 | 98,717,330.75 | | Net Profit | 71,351,134.60 | 77,487,478.51 | | Net Profit Attributable to Parent Company Shareholders | 69,695,705.61 | 66,627,574.62 | | Basic Earnings Per Share (CNY/share) | 0.34 | 0.32 | | Diluted Earnings Per Share (CNY/share) | 0.34 | 0.32 | [4、Parent Company Income Statement](index=49&type=section&id=4%E3%80%81Parent%20Company%20Income%20Statement) For the first half of 2025, the parent company's operating revenue was **0.90 million CNY**, with net profit of **45.87 million CNY**, a significant increase from the prior period Key Data from Parent Company Income Statement | Item | H1 2025 (CNY) | H1 2024 (CNY) | | :--- | :--- | :--- | | Operating Revenue | 897,020.76 | 0.00 | | Operating Profit | 45,843,552.37 | 13,729,007.55 | | Total Profit | 45,843,552.37 | 13,728,943.55 | | Net Profit | 45,868,270.60 | 13,796,050.88 | [5、Consolidated Cash Flow Statement](index=51&type=section&id=5%E3%80%81Consolidated%20Cash%20Flow%20Statement) For the first half of 2025, net cash flow from operating activities decreased by **21.48%**, investing activities saw a **181.87%** decrease, while financing activities increased by **212.07%**, resulting in a net decrease in cash and cash equivalents Key Data from Consolidated Cash Flow Statement | Item | H1 2025 (CNY) | H1 2024 (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 64,769,592.22 | 82,488,469.95 | | Net Cash Flow from Investing Activities | -204,528,984.17 | 249,826,475.75 | | Net Cash Flow from Financing Activities | 36,607,704.98 | -32,666,114.73 | | Net Increase in Cash and Cash Equivalents | -103,151,686.97 | 299,648,830.97 | [6、Parent Company Cash Flow Statement](index=52&type=section&id=6%E3%80%81Parent%20Company%20Cash%20Flow%20Statement) For the first half of 2025, the parent company reported negative net cash flows from operating and investing activities, with no financing cash flow, resulting in a net decrease in cash and cash equivalents Key Data from Parent Company Cash Flow Statement | Item | H1 2025 (CNY) | H1 2024 (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -8,875,833.41 | 137,569,277.32 | | Net Cash Flow from Investing Activities | -12,577,975.17 | 228,804,745.42 | | Net Cash Flow from Financing Activities | 0 | -14,767,891.92 | | Net Increase in Cash and Cash Equivalents | -21,453,808.58 | 351,606,130.82 | [7、Consolidated Statement of Changes in Owner's Equity](index=54&type=section&id=7%E3%80%81Consolidated%20Statement%20of%20Changes%20in%20Owner%27s%20Equity) For the first half of 2025, consolidated owner's equity increased by **30.52 million CNY**, driven by comprehensive income and profit distribution, with parent company equity increasing and minority interest decreasing - Consolidated owner's equity increased by **30.52 million CNY** for the first half of 2025[172](index=172&type=chunk) - Owner's equity attributable to the parent company increased by **39.65 million CNY**, while minority interest decreased by **9.13 million CNY**[172](index=172&type=chunk) - Total comprehensive income was **71.35 million CNY**, with distributions to owners (or shareholders) totaling **-40.83 million CNY**[172](index=172&type=chunk)[173](index=173&type=chunk) [8、Parent Company Statement of Changes in Owner's Equity](index=59&type=section&id=8%E3%80%81Parent%20Company%20Statement%20of%20Changes%20in%20Owner%27s%20Equity) For the first half of 2025, parent company owner's equity increased by **15.83 million CNY**, primarily due to comprehensive income and profit distribution - Parent company owner's equity increased by **15.83 million CNY** for the first half of 2025[181](index=181&type=chunk) - Total comprehensive income was **45.87 million CNY**, with distributions to owners (or shareholders) totaling **-30.04 million CNY**[181](index=181&type=chunk)[183](index=183&type=chunk) [Company Basic Information](index=63&type=section&id=%E4%B8%89%E3%80%81Company%20Basic%20Information) Sanbo Brain Hospital Management Group Co, Ltd, established in 2003 and listed in 2023, oper